Safety of infliximab in daily practice in patients with rheumatoid arthritis.

被引:0
作者
Neven, N
Vis, M
Voskuyl, AE
Wolbink, GJ
Nurmohamed, MT
Dijkmans, BAC
Lems, WF
机构
[1] Jan van Breemen Inst, Amsterdam, Netherlands
[2] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands
[3] Slotervaart Hosp, Amsterdam, Netherlands
来源
ARTHRITIS AND RHEUMATISM | 2003年 / 48卷 / 09期
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
786
引用
收藏
页码:S331 / S331
页数:1
相关论文
共 1 条
[1]   Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate:: a randomised phase III trial [J].
Maini, R ;
St Clair, EW ;
Breedveld, F ;
Furst, D ;
Kalden, J ;
Weisman, M ;
Smolen, J ;
Emery, P ;
Harriman, G ;
Feldmann, M ;
Lipsky, P .
LANCET, 1999, 354 (9194) :1932-1939